Activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are found in approximately 10-20% of non-small cell lung cancer (NSCLC) patients and are associated with response t...
Activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are found in approximately 10-20% of non-small cell lung cancer (NSCLC) patients and are associated with response to the EGFR inhibitors Gefitinib and ***
暂无评论